公开(公告)号：WO2011123946A8

公开(公告)日：2011-12-08

申请号：PCT/CA2011000386

申请日：2011-04-06

Applicant: UNIV HEALTH NETWORK ,  SAMPSON PETER BRENT ,  LIU YONG ,  LI SZE-WAN ,  FORREST BRYAN T ,  PAULS HEINZ W ,  EDWARDS LOUISE G ,  FEHER MIKLOS ,  PATEL NARENDRA KUMAR B ,  LAUFER RADOSLAW ,  PAN GUOHUA

Inventor： SAMPSON PETER BRENT ,  LIU YONG ,  LI SZE-WAN ,  FORREST BRYAN T ,  PAULS HEINZ W ,  EDWARDS LOUISE G ,  FEHER MIKLOS ,  PATEL NARENDRA KUMAR B ,  LAUFER RADOSLAW ,  PAN GUOHUA

IPC: C07D413/14 ,  A61K31/5377 ,  A61P35/00 ,  C07D403/04

CPC classification number: C07D403/10 ,  A61K31/5377 ,  A61K45/06 ,  C07D231/56 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14

Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: (I). Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

Abstract translation: 本发明涉及由以下结构式表示的化合物及其药学上可接受的盐：（I）。 由该结构式表示的化合物是激酶抑制剂，因此在此公开用于治疗癌症。 本文提供了结构式中变量的定义。

公开(公告)号：WO2009015485A1

公开(公告)日：2009-02-05

申请号：PCT/CA2008001415

申请日：2008-08-01

Applicant: UNIV HEALTH NETWORK ,  PAULS HEINZ W ,  FORREST BRYAN T ,  SAMPSON PETER BRENT ,  LIU YONG ,  LAUFER RADOSLAW ,  LANG YUNHUI ,  FEHER MIKIOS ,  YAO YI ,  PAN GUOHUA

Inventor： PAULS HEINZ W ,  FORREST BRYAN T ,  SAMPSON PETER BRENT ,  LIU YONG ,  LAUFER RADOSLAW ,  LANG YUNHUI ,  FEHER MIKIOS ,  YAO YI ,  PAN GUOHUA

IPC: C07D211/58 ,  A61K31/17 ,  A61K31/397 ,  A61K31/40 ,  A61K31/445 ,  A61P3/10 ,  A61P35/00 ,  C07C275/32 ,  C07D205/04 ,  C07D207/50 ,  C07D211/56

CPC classification number: C07D211/58 ,  C07C275/36 ,  C07D205/04 ,  C07D207/09 ,  C07D211/56 ,  C07D405/12

Abstract: A CPTl inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract translation: CPT1抑制剂化合物由结构式（I）或其药学上可接受的盐表示：或其药学上可接受的盐。 药物组合物包含由结构式（I）表示的化合物或其药学上可接受的盐。 治疗患有癌症的受试者的方法包括向受试者施用治疗有效量的由结构式（I）表示的化合物或其药学上可接受的盐。